Brief: Destiny Pharma Finalizes Phase 3 Development Plans For XF-73 NASAL
07/12/2022 07:29
Dec 7 (Reuters) - Destiny Pharma PLC DEST.L :
* DESTINY PHARMA PLC: FINALISATION OF ITS PHASE 3
DEVELOPMENT
PLANS FOR XF-73 NASAL; TARGETING PEAK SALES POTENTIAL OF $1
BILLION IN MAJOR MARKETS
Source text for Eikon: ID:nRSG8100Ia
Further company coverage: DEST.L